Aspen Neuroscience has announced six-month data from its Phase 1/2a ASPIRO clinical trial evaluating ANPD001, a personalized cell therapy for Parkinson’s disease. According to the company, the investigational therapy was generally well tolerated in the first five patients treated.
The company said that there were no dose-limiting toxicities, no serious adverse events related to the product, and no graft overgrowth observed on MRI scans. ANPD001 is an autologous cell therapy derived from each patient’s own induced pluripotent stem cells (iPSCs), designed to replace dopamine-producing neurons lost to Parkinson’s disease.
Aspen Neuroscience claims that early clinical observations showed encouraging signals, including improvements in patient-reported and clinician-assessed measures. However, the company noted that these findings are preliminary and the study was not powered to establish efficacy.
The ASPIRO trial is ongoing and aims to further assess the safety, feasibility, and potential biological effects of ANPD001 in people with moderate to severe Parkinson’s disease. According to the company, it also represents the first clinical trial to evaluate an autologous neuron replacement therapy in this patient population.
Aspen Neuroscience said it plans to share longer-term follow-up data and additional analyses as the study progresses. The company claims that these early results support continued development of its personalized approach to treating neurodegenerative disease.
